Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Clinuvel Pharmaceuticals (CUV) vs. Competitors

118 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
AU:CUVClinuvel Pharmaceuticals AUD 7.59AUD 383.20M11.16-31.50%Moderate BuyUnlock the AU:CUV analyst price target with TipRanks PremiumAU:CUVUnlock the AU:CUV top-analyst price target with TipRanks Premium
AU:ACRAcrux AUD 0.01AUD 5.82M-6.79-33.33%―Unlock the AU:ACR analyst price target with TipRanks PremiumAU:CUV vs AU:ACRUnlock the AU:ACR top-analyst price target with TipRanks Premium
AU:SPLStarpharma Holdings LimitedAUD 0.42AUD 202.82M-24.562.69%―Unlock the AU:SPL analyst price target with TipRanks PremiumAU:CUV vs AU:SPLUnlock the AU:SPL top-analyst price target with TipRanks Premium
AU:PYCPYC Therapeutics LimitedAUD 1.79AUD 1.76B-30.2933.88%Strong BuyUnlock the AU:PYC analyst price target with TipRanks PremiumAU:CUV vs AU:PYCUnlock the AU:PYC top-analyst price target with TipRanks Premium
AU:BOTBotanix Pharmaceuticals LimitedAUD 0.01AUD 22.10M-0.25-92.31%Moderate BuyUnlock the AU:BOT analyst price target with TipRanks PremiumAU:CUV vs AU:BOTUnlock the AU:BOT top-analyst price target with TipRanks Premium
AU:BIOBiome Australia LtdAUD 0.36AUD 83.31M22.36-18.18%Moderate BuyUnlock the AU:BIO analyst price target with TipRanks PremiumAU:CUV vs AU:BIOUnlock the AU:BIO top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
AU:CUVClinuvel Pharmaceuticals 7.59-3.53-31.74%
AU:ACRAcrux 0.01-0.01-37.50%
AU:SPLStarpharma Holdings Limited0.420.012.69%
AU:PYCPYC Therapeutics Limited1.790.5241.06%
AU:BOTBotanix Pharmaceuticals Limited0.01-0.12-92.31%
AU:BIOBiome Australia Ltd0.36-0.08-17.24%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts